文献速递免疫规划

三种RSVpreF疫苗批次在18-49岁健康成人中免疫原性等效:一项随机3期研究结果

Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
PubMed 文献 · Vaccine · 2024-04-16

这项3期、多中心、平行组、安慰剂对照、随机(1:1:1:1)、双盲研究评估了三种RSVpreF疫苗批次在18-49岁健康成人中的免疫原性、安全性和耐受性。参与者接种单剂120微克RSVpreF或安慰剂;接种后1个月,所有批次两两比较的RSV A和RSV B血清50%中和抗体几何平均滴度比值(GMR)95%CI均落在0.667-1.5区间内,满足1.5倍等效标准;三种批次均安全且耐受性良好,安全性特征相似。

要点

  • 三种RSVpreF批次两两比较的RSV A和RSV B中和抗体GMR 95%CI均在0.667-1.5内,满足1.5倍等效标准。
  • 接种后1个月RSV A和RSV B的50%中和抗体几何平均滴度较基线升高≥14倍。
  • 单剂120微克RSVpreF安全且耐受性良好,三种批次安全性特征相似。

核心结论

  • 三种RSVpreF疫苗批次的免疫原性满足预设的1.5倍等效标准,支持疫苗生产可重复性,且安全性和反应原性特征相似。

研究设计与样本

  • 3期、多中心、平行组、安慰剂对照、随机(1:1:1:1)、双盲研究,评估18-49岁健康成人接种单剂120微克RSVpreF或安慰剂。
  • 992名参与者接种疫苗,其中948名纳入可评估免疫原性人群。

主要发现

  • 所有三种RSVpreF批次均诱导强免疫应答,所有批次间比较在RSV A和RSV B上均满足1.5倍等效标准。
  • RSV A的50%中和抗体几何平均滴度从基线1671-1795升至接种后1个月24131-25238;RSV B从基线1358-1429升至19238-21702。
  • RSV A和RSV B从接种前至接种后1个月的50%中和滴度均升高≥14倍。
  • 单剂RSVpreF安全且耐受性良好,三种批次安全性特征相似。

关键数值与推荐

  • 批次间等效标准为1.5倍:每个批次对的两两比较GMR 95%CI均落在0.667-1.5区间内。
  • 免疫原性比较指标为接种后1个月RSV A和RSV B血清50%中和抗体几何平均滴度的GMR,分别比较。
  • 接种剂量为单剂120微克RSVpreF注射。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bivalent RSV prefusion F subunit vaccine (RSVpreF), comprised of equal quantities of stabilized prefusion F antigens from the major circulating subgroups (RSV A, RSV B), is licensed for prevention of RSV-associated lower respiratory tract illness (LRTI) in older adults and for maternal vaccination for prevention of RSV-associated LRTI in infants. To support licensure and large-scale manufacturing, this lot consistency study was conducted to demonstrate equivalence in immunogenicity across 3 RSVpreF lots. METHODS: This phase 3, multicenter, parallel-group, placebo-controlled, randomized (1:1:1:1), double-blind study evaluated immunogenicity, safety, and tolerability of RSVpreF in healthy 18-49-year-old adults. Participants received a single 120-µg injection of 1 of 3RSVpreF lots or placebo. Geometric mean ratio (GMR) of RSV serum 50 % neutralizing geometric mean titers obtained 1 month after vaccination were compared between each vaccine lot for RSV A and RSV B, separately. Equivalence between lots was defined using a 1.5-fold criterion (GMR 95 % CIs for every lot pair within the 0.667-1.5 interval). Safety and tolerability were assessed. RESULTS: Of 992participants vaccinated, 948 were included in the evaluable immunogenicity population. All 3 RSVpreF lots elicited strong immune responses, meeting the 1.5-fold equivalence criterion for all between-lot comparisons for both RSV A and RSV B. Across the 3 lots, RSV A and RSV B 50 % neutralizing geometric mean titers substantially increased from baseline (RSV A, 1671-1795; RSV B 1358-1429) to 1 month after RSVpreF vaccination (RSV A, 24,131-25,238; RSV B, 19,238-21,702), corresponding to ≥14-fold increases in 50 % neutralizing titers for both RSV A and RSV B from before to 1 month after vaccination. Single doses of RSVpreF were safe and well tolerated, with similar safety profiles across the 3 RSVpreF lots. CONCLUSIONS: These findings support the reproducibility of RSVpreF vaccine manufacturing with similar safety and reactogenicity profiles (NCT05096208).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Baker J, Aliabadi N, Munjal I, et al. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study. Vaccine. 2024. PMID: 38616438. doi:10.1016/j.vaccine.2024.03.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。